1. Generics Bulletin
  2. >>Products

Teva Settles With Pfizer Over Xeljanz XR As 2025 Date Looms

Israeli Firm Previously Sued Over Patent Expiring In 2034

 
• By Dean Rudge

Teva has opted against litigating with Pfizer over its controversial Xeljanz XR JAK inhibitor, settling patent infringement proceedings over a US patent scheduled to expire in 2034. Zydus Cadila recently bagged 180 days of exclusivity for a strength of its ANDA product.

women's handshake
Teva was sued by Pfizer at the end of 2018 • Source: Alamy

Teva Pharmaceutical Industries Ltd. has agreed to settle and dismiss US patent litigation with Pfizer over intellectual property shielding the originator’s Xeljanz XR (tofacitinib) 11mg extended-release tablets blockbuster treatment for autoimmune diseases.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

More from Products